Potential clinical value of circulating chromogranin A in patients with prostate carcinoma

Annals of Oncology

Volumn 12, Issue SUPPLE. 2, 2001, Pages

  Berruti, A ^a   Dogliotti, L ^a   Mosca, A ^a   Gorzegno, G ^a   Bollito, E ^a   Mari, M ^a   Tarabuzzi, R ^a   Poggio, M ^a   Torta, M ^a   Fontana, D ^a   Angeli, A ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Chromogranin A; Neuroendocrine differentiation; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN; ANGIOPEPTIN; CHROMOGRANIN A; OCTREOTIDE; PROSTATE SPECIFIC ANTIGEN; SOMATOSTATIN DERIVATIVE;

BENIGN TUMOR; BLOOD LEVEL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER THERAPY; CHEMOTHERAPY; CIRCULATION; CONTROLLED STUDY; DATA ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NEUROENDOCRINE SYSTEM; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PROSTATE TUMOR; PUBLICATION; REVIEW; TISSUE DIFFERENTIATION;

EID: 0035174379     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/12.suppl_2.s153     Document Type: Review

References (42)

1. Neuroendocrine differentiation in carcinoma of the prostate: Diagnostic, prognostic and therapeutic implications
2. Prostatic carcinoma. Histological and immuno-histological factors affecting prognosis
3. Immunoassay and immunohistological studies of chromogranin as a neuroendocrine marker in patients with carcinoma of the prostate
4. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long term follow-up study with patients treated by radical prostatectomy
5. Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status
6. The prostatic endocrine paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research
7. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer
8. Neuroendocrine differentiation in prostate carcinoma
9. Characterization of circulating chromogranin A in human cancer patients
10. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy
11. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors
12. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate
13. Serum chromogranin A in prostate cancer. Preliminary results
14. Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy
15. Serum Chromogranin A in monitoring metastatic prostate cancer patients
16. Circulating neuroendocrine markers in patients with prostate carcinoma
17. Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings?
18. Elevated plasma chromogranin A concentrations in prostatic carcinoma
19. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma
20. Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients
21. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors
22. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma
23. Clinical significance of elevation of neuroendocrine factors and interleukin-6 in metastatic prostate cancer
24. Prostate specific antigen in staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia
25. Low PSA metastatic androgen-independent prostate cancer
26. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an 'endocrine marker'
27. APUDtype endocrine tumor of the prostate: Incidence and prognosis in association with adenocarcinoma
28. Peptide hormone- and serotonin-immunoreactive cells in carcinoma of the prostate
29. The course of neuroendocrine differentiation in prostatic carcinomas: An immunohistochemical study testing chromogranin A as an 'endocrine marker'
30. Simultaneous detection of DNA fragmentation (apoptosis), cell proliferation (MIB-1), and phenotype markers in routinely processed tissue sections
31. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients
32. Effect of chromogranin A (pancreastatin) fragment on invasion of prostate cancer cells
33. Androgen deprivation of the prohormone convertase-310 human prostate cancer model system induces neuroendocrine differentiation
34. Octreotide
35. Treatment of carcinoid syndrome with long-acting somatostatin analogue Lanreotide: A prospective study in 39 patients
36. The role of somatostatin analogs in the treatment of gastro-entero-pancreatic endocrine tumors
37. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience
38. High-dose treatment with Lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: Clinical and biological effects
39. Effect of lanreotide administration on circulating levels of chromogranin A and prostatic specific antigen in advanced prostate cancer patients
40. Distribution of somatostatin receptors in normal and neoplastic human tissues: Recent advances and potential relevance
41. Different expression patterns of somatostatin receptors subtypes in cultured epithelial cells from human normal prostate and prostate cancer
42. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111-In]-labeled DTPA-d-[Phe]-Octreotide scintigraphy